New vaccine aims to shield kids from deadly meningitis
NCT ID NCT07505888
First seen Apr 16, 2026 · Last updated Jun 23, 2026 · Updated 11 times
Summary
This phase 3 trial tests a new meningococcal conjugate vaccine in 660 healthy children aged 2 to 6 years. The vaccine targets four strains of the bacteria that cause meningitis and bloodstream infections. Participants receive one shot and provide blood samples to measure immune response. The goal is to see if the new vaccine works as well as the current licensed vaccine and is safe for children.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EPIDEMIC MENINGITIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
group ACYW135 meningococcal conjugate vaccine
What this could lead to
If successful, this could provide a safer and more effective vaccine option to protect young children against four types of meningococcal disease.
What could go wrong
This is a phase 3 trial, but results may not confirm superiority or non-inferiority. The vaccine could cause side effects like pain or fever, and long-term protection is not yet known.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.